For the quarter ending 2026-03-31, FDMT made $3,047K in revenue. -$68,760K in net income. Net profit margin of -2256.65%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration and license revenue | 3,047 | 85,090 | 90 | 15 |
| Research and development | 64,980 | 57,608 | 49,438 | 47,951 |
| General and administrative | 11,687 | 12,767 | 11,837 | 11,520 |
| Total operating expenses | 76,667 | 70,375 | 61,275 | 59,471 |
| Gain from operations | -73,620 | 14,715 | -61,185 | -59,456 |
| Interest income | 4,864 | 4,704 | 4,330 | 4,859 |
| Other income (expense), net | -4 | -22 | -21 | -61 |
| Total other income, net | 4,860 | 4,682 | 4,309 | 4,798 |
| Net gain | -68,760 | 19,397 | -56,876 | -54,658 |
| Basic EPS | -1.01 | 0.303 | -1.01 | -0.98 |
| Diluted EPS | -1.01 | 0.303 | -1.01 | -0.98 |
| Basic Average Shares | 68,064,586 | 63,923,252 | 56,126,330 | 55,927,091 |
| Diluted Average Shares | 68,064,586 | 63,923,252 | 56,126,330 | 55,927,091 |
4D Molecular Therapeutics, Inc. (FDMT)
4D Molecular Therapeutics, Inc. (FDMT)